Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefepime + taniborbactam versus meropenem for complicated urinary tract infection
2018-001451-13Phase 3Completed
- Sponsor
- Venatorx Pharmaceuticals
- Start
- Mar 2019
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cefepime and taniborbactam in complicated urinary tract infection (cUTI) and acute pyelonephritis (2 arms), sponsored by Venatorx Pharmaceuticals. Primary endpoint: Composite microbiological and symptomatic success at test of cure in the microITT population. Started Mar 2019; status: completed.
02
Drugs
cefepimetaniborbactam
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on 2018-001451-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001451-13.